06:07

Elranatamab for R/R myeloma: long-term updates from MagnetisMM-3 & real-world safety of this agent

01:37

Integrating BCMA-targeted immunotherapies into challenging multiple myeloma cases

01:23

Navigating patient burden in PNH

01:53

Considering the optimal treatment strategy for patients with genetically high-risk CLL

02:18

The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML

01:28

Epcoritamab in R/R FL: pooled efficacy data from EPCORE NHL-1

01:45

The real-world outcomes of patients with CLL who discontinue BTKi therapy

01:24

Mechanisms of resistance to FLT3 inhibitors in AML and strategies to overcome this

00:56

Considering individual patient goals and preferences in CLL

02:31

Sonrotoclax plus dexamethasone in patients with R/R myeloma harboring t(11;14): a Phase Ib/II trial

01:00

The association between hemophilia and fracture risk

00:48

Updates and correlative results from the MANIFEST-2 trial

02:16

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

01:30

Immunophenotypic changes induced by menin inhibition in AML

02:15

Extending remission in patients with AML who become eligible for alloSCT following targeted therapy

01:51

The major risk factors for infection in CLL and exploring strategies to mitigate risk

01:21

CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamab

03:34

TRANSCEND-CLL-004: pivotal in the FDA approval of liso-cel for R/R CLL

01:25

Strategies to improve the efficacy of CAR-Ts in CLL

00:40

The impact of an evolving first-line setting on subsequent treatment lines in multiple myeloma

03:19

Addressing cardiotoxicity in patients with CLL using BTK inhibitors

01:18

Involving the patient in treatment decisions for CLL

04:03

A novel armored CAR-T that shows promise in R/R lymphomas following anti-CD19 CAR-T failure

03:59

3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCL

01:34

Follow-up from the COMMANDS trial beyond the primary endpoint: luspatercept versus ESA-based therapy

02:17

Emerging therapies to address the unmet need for triple-class refractory multiple myeloma

01:27

BCMA-targeted CAR-T therapy is tolerable in multiple myeloma with CNS involvement

01:01

Advancements in CML: improving treatment-free remission and novel agents

01:37

EO2463: a vaccine as a monotherapy or in combination with standard chemotherapy in NHL

03:32

Can early detection of multiple myeloma improve patient outcomes?

04:38

The potential of MRD-adapted treatment in multiple myeloma

01:40

Pivekimab sunirine in combination with venetoclax and azacitidine for CD123-positive AML

02:23

Improving treatment for patients with TP53-mutated myeloid malignancies

05:19

The current treatment landscape for multiple myeloma and trials investigating novel combinations

07:48

Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCL

08:06

Findings from arms 6 and 7 of the EPCORE NHL-2 trial: epcoritamab in newly diagnosed FL

01:18

The importance of protecting cardiovascular health in cancer patients

01:22

Shortening the duration of treatment with fixed-duration or MRD-adapted regimens in CLL

03:42

Novel approaches to bridging prior to CAR-T therapy in multiple myeloma

01:57

Sequencing immunotherapies in multiple myeloma

02:59

KTd versus KRd followed by maintenance or observation in elderly patients with multiple myeloma

02:06

Improving the accuracy of infection reporting in myeloma clinical trials

01:49

Global disparities in multiple myeloma treatment and clinical trials

00:54

The experience of single-agent daratumumab for R/R myeloma in India

01:01

India's first sequential hematopoietic stem cell and kidney transplant for multiple myeloma

01:41

Treating and understanding the biology of extramedullary disease in myeloma

01:06

Long-term outcomes of the OCEAN study: melflufen is superior to pomalidomide in R/R myeloma

00:42

Challenges with designing clinical trials for smoldering myeloma

04:30

MRD testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trials

02:20

Manipulating the gut microbiome to change outcomes of multiple myeloma

04:58

The potential of IPH6501, a tetraspecific antibody-based NK cell engager, for NHL

01:25

An update on the EMN19 study: Dara-VCd in multiple myeloma

02:39

An update on the ELiPSE-1 study: safety data from patients treated with CNTY-101, a CAR-NK therapy

03:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

01:29

BELLWAVE-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve CLL/SLL

03:02

Quadruplets vs triplets in newly diagnosed myeloma: is more better?

01:31

Five-year follow-up of olutasidenib for IDH1-mutated R/R AML

02:08

Longer-term follow-up of prophylactic tocilizumab for the reduction of CRS in the MajesTEC-1 trial

02:06

The outcomes of dara-VTd in patients with treatment-naive systemic AL amyloidosis

03:15

The current state of cardiac transplantation for AL and ATTR amyloidosis